Arvinas (ARVN) CSO share sale covers RSU tax withholding

Rhea-AI Filing Summary

Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic share sale tied to tax withholding. On May 11, 2026, she sold 9,657 shares of common stock at $9.9374 per share. According to the footnote, this sale was made by the company to cover tax obligations from the vesting and settlement of RSUs granted on May 9, 2025 and "does not represent a discretionary trade." After the transaction, she directly owned 182,966 shares of Arvinas common stock.

Insider Trade Summary

Net Seller: 9,657 shares ($95,965)

Net Sell 1 txn

Insider Cacace Angela M

Role Chief Scientific Officer

Sold 9,657 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,657	$9.9374	$96K

Holdings After Transaction: Common Stock — 182,966 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 9,657 shares Sale price per share: $9.9374 per share Shares owned after transaction: 182,966 shares +1 more

4 metrics

Shares sold 9,657 shares Common stock sold on May 11, 2026

Sale price per share $9.9374 per share Price for the 9,657 common shares sold

Shares owned after transaction 182,966 shares Directly owned following the May 11, 2026 sale

RSU grant date May 9, 2025 Restricted stock units whose vesting triggered tax sale

Key Terms

restricted stock units (RSUs), tax withholding obligations, vesting and settlement, non-derivative

4 terms

restricted stock units (RSUs) financial

"in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

tax withholding obligations financial

"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement"

vesting and settlement financial

"in connection with the vesting and settlement of one-half of the reporting person's restricted stock units"

non-derivative financial

"transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cacace Angela M

(Last) (First) (Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN CONNECTICUT 06511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S		9,657(1)	D	$9.9374	182,966	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arvinas (ARVN) disclose for Angela M. Cacace?

Arvinas disclosed that Chief Scientific Officer Angela M. Cacace had 9,657 common shares sold on May 11, 2026 at $9.9374 per share. The sale was automatic to cover tax withholding from RSU vesting and was not a discretionary trade.

Was the Angela M. Cacace share sale in Arvinas (ARVN) a discretionary trade?

No, the filing states the sale does not represent a discretionary trade. The issuer executed the sale automatically to satisfy tax withholding obligations related to vesting and settlement of previously granted restricted stock units.

How many Arvinas (ARVN) shares did Angela M. Cacace hold after the reported sale?

After the automatic tax-related sale, Angela M. Cacace directly held 182,966 shares of Arvinas common stock. This post-transaction holding figure is disclosed in the Form 4 as the total shares beneficially owned following the transaction.

What was the price per share for Angela M. Cacace’s Arvinas (ARVN) sale?

The reported transaction price was $9.9374 per share for the 9,657 Arvinas common shares sold. This price reflects the execution level used when the issuer sold shares to cover tax withholding from vested RSUs.

Why did Arvinas sell shares from Angela M. Cacace’s holdings?

Shares were sold automatically to cover tax withholding obligations tied to the vesting and settlement of one-half of her restricted stock units granted on May 9, 2025. The company executed the sale, and it was not a voluntary market trade.